- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | VITRAFY LIFE SCIENCES LIMITED: 2026 Notice of Annual General Meeting | - | ASX | ||
| 06.10. | VITRAFY LIFE SCIENCES LIMITED: Investor Roadshow Presentation | - | ASX | ||
| 06.10. | VITRAFY LIFE SCIENCES LIMITED: Change to CEO Remuneration and Employment Terms | - | ASX | ||
| 30.09. | Daily Special: INOVIQ, Immutep, First Graphene, Mayne Pharma, Vitrafy Life Sciences | 21 | Finance News Network | ||
| 30.09. | Vitrafy Life Sciences Expands Platelet Cryopreservation Program With Versiti Blood Health | 1 | smallcaps.com.au | ||
| 30.09. | Vitrafy Life Sciences Forges Key Partnership with Versiti Blood Health for Platelet Cryopreservation | 1 | Finance News Network | ||
| 30.09. | VITRAFY LIFE SCIENCES LIMITED: Vitrafy enters partnership with Versiti Blood Health | 1 | ASX | ||
| 02.09. | Vitrafy Life Sciences Enters US Cell and Gene Therapy Space with Cryopreservation Agreement | 1 | smallcaps.com.au | ||
| VITRAFY LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 02.09. | VITRAFY LIFE SCIENCES LIMITED: Vitrafy enters U.S. Cell & Gene Therapy Market | 1 | ASX | ||
| 04.08. | Vitrafy FY2026 slides: blood crisis fuels commercial momentum | 2 | Investing.com | ||
| 04.08. | Vitrafy FY26 slides: blood crisis drives partnerships, FDA filing ahead | 1 | Investing.com | ||
| 04.08. | VITRAFY LIFE SCIENCES LIMITED: FY26 Corporate Governance Statement | 1 | ASX | ||
| 04.08. | VITRAFY LIFE SCIENCES LIMITED: FY26 Full Year Results Presentation | 2 | ASX | ||
| 04.08. | VITRAFY LIFE SCIENCES LIMITED: FY26 Appendix 4G | 1 | ASX | ||
| 04.08. | VITRAFY LIFE SCIENCES LIMITED: FY26 Appendix 4E and Annual Report | 2 | ASX | ||
| 03.08. | VITRAFY LIFE SCIENCES LIMITED: Vitrafy FY26 Investor Briefing | 1 | ASX | ||
| 28.07. | VITRAFY LIFE SCIENCES LIMITED: Q4 FY26 Quarterly Activities Report and Appendix 4C | - | ASX | ||
| 23.07. | Health Check: Vitrafy addresses looming US platelet shortage with US blood bank collab | 1 | Stockhead | ||
| 23.07. | VITRAFY LIFE SCIENCES LIMITED: Vitrafy enters a partnership with Hoxworth Blood Center | - | ASX | ||
| 22.07. | VITRAFY LIFE SCIENCES LIMITED: Application for quotation of securities - VFY | - | ASX |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,030 | -0,24 % | QIAGEN N.V.: QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis | Global TB Summit brings together international experts as persistent disease burden and funding pressures challenge progress against tuberculosis QuantiFERON-TB Gold Plus detects tuberculosis... ► Artikel lesen | |
| IMMUNOVANT | 26,730 | 0,00 % | Immunovant Q1 2027 Earnings Call: Complete Transcript | ||
| RECURSION PHARMACEUTICALS | 3,465 | 0,00 % | Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here's What You Should Know | ||
| PRAXIS PRECISION MEDICINES | 241,79 | +0,01 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 37,320 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year | Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness
Enliven continues preparation for late-stage... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 37,950 | 0,00 % | HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? | ||
| ERASCA | 13,375 | -0,11 % | Erasca drops after sacking COO | ||
| MODERNA | 193,00 | -0,52 % | Moderna-Aktie: +14% an einem Tag - was treibt den Kurs? | Moderna hat am Freitag einen der stärksten Handelstage des Jahres hingelegt. Die Aktie sprang um +14,2% auf 225 US$ und markierte damit gleichzeitig ein neues 52-Wochen-Hoch. Rückenwind kam von neuen... ► Artikel lesen | |
| COGENT BIOSCIENCES | 29,550 | +0,10 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| NURIX THERAPEUTICS | 24,400 | 0,00 % | Nurix Therapeutics Swings To Profit In Q3 On Roche Licensing Revenue | SOUTH SAN FRANCISCO (dpa-AFX) - Nurix Therapeutics, Inc. (NRIX), clinical-stage biopharmaceutical company, reported a swing to profit in the third quarter from a loss in the year-ago period... ► Artikel lesen | |
| TANGO THERAPEUTICS | 22,050 | +0,05 % | Tango Therapeutics, Inc.: Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026 | ||
| TARSUS PHARMACEUTICALS | 68,06 | -0,01 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 28,840 | +0,07 % | Why Is Arcutis Biotherapeutics Stock Surging Thursday? | ||
| CITY THERAPEUTICS | 22,030 | -1,65 % | US IPO Weekly Recap: Biotechs City Therapeutics and Iambic headline the week's pricings | ||
| SUMMIT THERAPEUTICS | 14,650 | +0,14 % | Summit Therapeutics Secures $2B Strategic Investment From AstraZeneca | LONDON (dpa-AFX) - Summit Therapeutics Inc. (SMMT) on Monday announced the closing of AstraZeneca's (AZN) $2 billion strategic equity investment, which will support accelerated development of... ► Artikel lesen |
Das Unternehmen VITRAFY LIFE SCIENCES LIMITED kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VITRAFY LIFE SCIENCES LIMITED finden Sie auf Wallstreet Online.